e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Lung cancer: molecular pathology and functional genomics
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The clinical significance of plasma DNA quantification in NSCLC
A. Szpechcinski, K. Maszkowska-Kopij, W. Kupis, J. Zaleska, E. Radzikowska, R. Struniawski, E. Puscinska, T. Orlowski, P. Sliwinski, K. Roszkowski-Sliz, J. Chorostowska-Wynimko (Warsaw, Poland)
Source:
Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Session:
Lung cancer: molecular pathology and functional genomics
Session type:
Poster Discussion
Number:
1954
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Szpechcinski, K. Maszkowska-Kopij, W. Kupis, J. Zaleska, E. Radzikowska, R. Struniawski, E. Puscinska, T. Orlowski, P. Sliwinski, K. Roszkowski-Sliz, J. Chorostowska-Wynimko (Warsaw, Poland). The clinical significance of plasma DNA quantification in NSCLC. Eur Respir J 2011; 38: Suppl. 55, 1954
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
The detection of quantitative serum p53 protein in lung cancer and its clinical value
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
The predictive value of total vs. amplificable free-circulating DNA in plasma of NSCLC patients – a preliminary study
Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Year: 2008
Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer
Source: Annual Congress 2009 - Basic science and lung cancer
Year: 2009
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Real-time PCR analysis of free-circulating DNA in plasma of non-small cell lung cancer patients
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
Source: Eur Respir J 2015; 46: 1773-1780
Year: 2015
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010
The clinical significance of soluble E-cadherin in lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 769s
Year: 2006
Prognostic significance of plasma D-dimer (DD) in lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002
Quantitative methylation profiles of multiple genes in patients with non-small cell lung cancer and its association with clinicopathological correlations
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
PTGER4, a promising novel DNA methylation marker for lung cancer measured in a clinical case control study using blood plasma
Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Year: 2008
Plasma DNA concentration and integrity measurement for NSCLC diagnostics and radical therapy effectiveness monitoring
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer?
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008
Clinical significance of serum osteopontin levels in lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Small cell lung cancer: prognostic significance and correlation with clinical and laboratory parameters
Source: Eur Respir J 2007; 30: Suppl. 51, 670s
Year: 2007
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
The clinical significance of plasma and urine lysophospholipids-producing enzymes in patients with sarcoidosis
Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Year: 2020
Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
Clinical significance of serum adipokines levels in lung cancer
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept